Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Mol Pharm. 2015 May 4;12(6):2101–2111. doi: 10.1021/acs.molpharmaceut.5b00071

Figure 6. CD19-targeting increases the cell associated DOX (intracellular and cell surface bound, caDOX) levels in RS4;11 cells.

Figure 6

(A) HPLC/MS/MS representative quantitation of caDOX levels in REH and RS4;11 cells treated with CD19-DOX-NPs (≈1μM DOX, for 1h at 37°C). (B) REH and RS4;11 caDOX levels on treatment with free DOX for 1h at 37°C. (C) REH and RS4;11 caDOX levels on treatment with CD19-DOX-NPs for 1h at 37°C. Quantified data shown are averages of three independent experiments. Statistical significance was determined using the Holm-Sidak method, with alpha = 5.000%.